MORE►
Biopharmaceuticals
Left: Milan Radovich, SVP and Chief Scientific Officer at Caris Life Sciences; Right: Boris L. Zaïtra, Head of Roche Corporate Business Development [Photos: LinkedIn/Roche]
North Texas’ Caris Life Sciences To Collaborate With Genentech on Novel Therapeutic Targets for Cancers
by Sandra Engelland | Dec 17, 2025
Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25 million and is also eligible for up to $1.1 billion of potential research, development, commercial, and net sales payments, as well as potential tiered royalties on net sales of collaboration therapies, the company said.
by Sandra Engelland |
Nov 20, 2025
With more than two decades of experience in product development, strategic operations, and commercial execution across the biotechnology industry, Brent Sorrells will help drive OncoNano’s next phase of growth and operational excellence, the company said.
MORE►
by Quincy Preston |
Jul 26, 2023
From an old car parts garage, Vertex Founder Joshua Boger launched the Boston-based biotech giant in 1989, running it for two decades as CEO. Boger "unretired" in June to join fast-moving Alkeus Pharmaceuticals as executive chairman.
In Dallas, he shared the "mistakes" that led to his success with innovators at Pegasus Park. Here's his no-holds-barred dose of truth for all entrepreneurs.
In Dallas, he shared the "mistakes" that led to his success with innovators at Pegasus Park. Here's his no-holds-barred dose of truth for all entrepreneurs.
MORE►
by Lance Murray |
Feb 15, 2023
Dallas-based Financial Strategies Acquisition Corp. has acquired Texas-based preclinical pharmaceutical company Austin Biosciences Corp.
Financial Strategies is a special purpose acquisition company led by CEO Alexander V. Schinzing. It said that upon the deal’s closing, Austin Biosciences will become a wholly owned subsidiary of the company.
Earlier this month, Financial Strategies announced that its board approved an extension of the period of time available to consummate the deal by one month from Feb....
MORE►
Photo: Jun/iStock
With $16.5M in New Funding, Fort Worth’s Nacuity Aims to Treat ‘Serious Blinding and Chronic Diseases’
by Kevin Cummings | Jun 15, 2022
Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials.
“This funding will help further our mission to develop a breakthrough treatment for retinitis pigmentosa and other serious blinding and chronic diseases," said Nacuity Chairman, CEO, and Co-founder Halden Conner.
MORE►
